Online Database of Chemicals from Around the World

2-[4-(1-羟基-4-{4-[羟基(二苯基)甲基]-1-哌啶基}丁基)苯基]-2-甲基丙酸
[CAS# 139965-11-0]

供应商
APIChem Technology Co., Ltd. 中国 询价快递  
+86 (571) 8678-2096
sales@apichemistry.com
化学品生产商(2009 年起)
Alfa Chemistry 美国 询价快递  
+1 (201) 478-8534
inquiry@alfa-chemistry.com
化学品供销商(2012 年起)
chemBlink 标准供应商(2012 年起)
AvaChem Scientific LLC 美国 询价快递  
+1 (210) 667-3815
chemsupply@avachem.com
化学品生产商
ChemDiv, Inc. 美国 询价快递  
+1 (858) 794-4860
chemdiv@chemdiv.com
化学品生产商
ChemPacific Corp 美国 询价快递  
+1 (410) 633-5771
sales@chempacific.com
化学品生产商(1995 年起)
Glentham Life Sciences 英国 询价快递  
+44 (2033) 978-798
info@glenthamls.com
化学品供销商(2013 年起)
Interbioscreen Ltd. 俄罗斯 询价快递  
+7 (49) 6524-0091
screen@ibscreen.chg.ru
化学品生产商
Matrix Scientific Inc. 美国 询价快递  
+1 (803) 788-9494
sales@matrixscientific.com
化学品生产商
OX CHEM 美国 询价快递  
+1 (626) 461-2812
sales@ox-chem.com
受托研究(2013 年起)
Paragos e. K. 德国 询价快递  
+49 2330-8079751
sales@paragos.de
化学品生产商(2001 年起)
Santa Cruz Biotechnology, Inc. 美国 询价快递  
+1 (831) 457-3800
scbt@scbt.com
化学品生产商
ZereneX Molecular Ltd. 英国 询价快递  
+44 (1204) 527-700
sales@zerenex-molecular.com
化学品生产商
基本信息
产品名称 2-[4-(1-羟基-4-{4-[羟基(二苯基)甲基]-1-哌啶基}丁基)苯基]-2-甲基丙酸
英文名 2-[4-(1-Hydroxy-4-{4-[Hydroxy(Diphenyl)Methyl]-1-Piperidinyl}Butyl)Phenyl]-2-Methylpropanoic Acid
别名 Terfenadine carboxylate; 153439-40-8 83799-24-0; 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid
分子式 C32H39NO4
分子量 501.66
CAS 登录号 139965-11-0
分子行输入简码 SMILES CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O
国际化学标识码 InChI 1S/C32H39NO4/c1-31(2,30(35)36)25-17-15-24(16-18-25)29(34)14-9-21-33-22-19-28(20-23-33)32(37,26-10-5-3-6-11-26)27-12-7-4-8-13-27/h3-8,10-13,15-18,28-29,34,37H,9,14,19-23H2,1-2H3,(H,35,36)
国际化学标识检索码 InChIKey RWTNPBWLLIMQHL-UHFFFAOYSA-N
物理化学性质
密度 1.2±0.1g/cm3 (计算值)
沸点 697.3±55.0°C at 760 mmHg (计算值)
闪点 375.5±31.5°C (计算值)
折射率 1.597 (计算值)
安全数据
安全说明 IRRITANT
参考文献
(1) Kenneth E. Thummel and Danny D. Shen. Percentage Binding in Plasma, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Bound in Plasma' (%) values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had 'Bound in Plasma' values indicated for them have been provided in the files here. Structures (and values) for Clavulanate (22), Heparin (Extensive), Lithium (0), Mycophenolate (MPA: 97.5), Prednisolone (90-95 (<200 ng/ml), ~70(>1 microgm/ml)) and Rapacuronium (50-88) have not been provided here. In all, 280 drugs and their 'Bound in Plasma' values (%) are given in the files here.
(2) Kenneth E. Thummel and Danny D. Shen. Peak Time, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Peak-Time' values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. These are in hours unless otherwise indicated. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had 'Peak-Time' values indicated for them have been provided in the files here. Structures (and values) for Clavulanate (1.3), Enoxaparin (3), Epoetin Alfa (SC: 18, IP:12), Etanercept (SC-SD:72(48-96)), Filgrastim (4-5.8), Heparin (3), Interferon Alfa (IM:3.8,SC:7.3), Interferon Beta (SC:1-8), Lithium (IR:0.5-3, SR:2-6), Mycophenolate (MPA: 1.1-2.2), Prednisolone (1.5+-0.5), Sargramostim (A,SC: 1-3, C,SC:1.5-4) and Streptokinase (0.9+-0.21) have not been provided here. In all, 270 drugs and their 'Peak-Time' values are given in the files here.
(3) Kenneth E. Thummel and Danny D. Shen. Urinary Excretion, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023Urinary Excretion (%) values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had Urinary Excretion values indicated for them have been provided in the files here. Structures (and values) for Alteplase (t-PA) (Low), Clavulanate (43+-14), Enoxaparin (43), Epoetin alfa (<3), Etanercept (Negligible), Heparin (Negligible), Lithium (95+-15), Mycophenolate (MPA: <1), Prednisolone (26+-9), Rapacuronium (6-22) and Streptokinase (0) have not been provided here. In all, 297 drugs and their Urinary Excretion values (%) are given in the files here.
(4) Kenneth E. Thummel and Danny D. Shen. Peak Concentration, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Peak-Concentrations' values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. The units are indicated along with the values. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Structures (and values) for Alteplase (t-PA) (973+-133 ng/ml), Clavulanate (2.8 micro g/ml), Enoxaparin (ACLM: 145+-45 ng/ml, BCLM: 414+-87 ng/ml), Epoetin Alfa (SC: 176+-75 U/l, IP: 375+-123 U/l), Etanercept (IV:2.32 micro-g/ml, SC-SD:1.2 micro-g/ml, SC-MD 3 micro-g/ml), Filgrastim (SC: 4 and 49 ng/ml), Heparin (70+-39 ng/ml), Infliximab (118 micro-g/ml), Interferon Alfa (IV: ~13 ng/ml, IM: 2.0 (1.5-2.6) ng/ml, SC: 1.7 (1.2-2.3) ng/ml), Interferon Beta (IV: 1491+-659 IU/ml, SC: 40+-20 IU/ml), Lithium (IR: 1-2 mM, SR: 0.7-1.2 mM), Mycophenolate (MPA: 8-19 micro-g/ml), Prednisolone (458+-150 ng/ml), Rapacuronium (6-20 micro-g/ml), Sargramostim (A, IV: 5ng/ml, A, SC: 1.5 ng/ml, C, IV: 100 ng/ml, C, SC: 10 ng/ml) and Streptokinase (188+-58 IU/ml) have not been provided here. In all, 304 drugs and their 'Peak-Concentration' values are given in the files here.
(5) Kenneth E. Thummel and Danny D. Shen. Clearance , "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Clearance' values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. These are in (ml/min/kg) units unless otherwise indicated. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had 'Clearance' values indicated for them have been provided in the files here. Structures (and values) for Alteplase (t-PA) (10+-4), Clavulanate (3.6+-1.0), Enoxaparin (0.3+-0.1), Epoetin Alfa (0.047+-0.017 (0.047-0.092)), Etanercept (0.02), Filgrastim (0.5-0.7), Heparin (1/(0.65 + 0/0.008D) +- 0.1), Interferon Alfa (2.8+-0.6), Interferon Beta (13+-5), Lithium (0.35+-0.11), Mycophenolate (MM: 120-163, MPA: 2.5+-0.4), Prednisolone (1.0+-0.16), Rapacuronium (7-11), Sargramostim (A: 420 ml/min/(m.m), C:49(15-118) ml/min/(m.m)) and Streptokinase (1.7+-0.7) have not been provided here. In all, 301 drugs and their 'Clearance' values are given in the files here.
市场分析报告
请浏览2-[4-(1-羟基-4-{4-[羟基(二苯基)甲基]-1-哌啶基}丁基)苯基]-2-甲基丙酸市场分析报告总目录
相关产品
2-羟基-4-[3-(三氟甲基...  (2S)-2-[(3R)-3-...  3-[1-羟基-4-[4-(羟...  4-[1-羟基-4-[4-(羟...  (3R,4R,5S)-3-羟基...  2-羟基-4-[2-羟基-6-...  (3aR,4R,5R,6aS)...  5-羟基-4-{[(3-硝基苯...  N'-羟基-4-{[5-(三氟...  2-({4-[(2-羟基-4-...  4-羟基-4’-(三甲基乙酰氧...  (S)-4-羟基4’-甲氧基普...  (4aR,4bS,6aS,7S...  (1S,2R,4aS,6aR,...  1-[(4aR,8aS)-8a...  1-[(1R,4aR,8aR)...  1-[(1R,4aS,8aS)...  8a-羟基-4a-甲基-十氢萘...  2-羟基-4-氨基-2,4,6...  2-羟基-4-氨基-5-氯-N...